Trial Profile

A Phase1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2025 According to a Sarepta Therapeutics media release, this trial is one of the clinical-stage programs covered under the collaboration agreement with Arrowhead Pharmaceuticals, under which Sarepta has obtained exclusive global rights from Arrowhead to four clinical-stage and three preclinical-stage programs.
26 Nov 2024 According to an Arrowhead Pharmaceuticals media release, company is currently dosing patients in a Phase 1/2 clinical study.
24 Oct 2024 Planned number of patients changed from 52 to 60.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com